How is Venclexta (venetoclax) used for AML?

Drugs.com

Official answer

by Drugs.com

When used to treat AML (acute myeloid leukemia) Venclexta is given as an increasing dose for the first few days, with the maintenance dose starting on the fourth day. The exact maintenance dose depends on the combination agent used, which is usually either azacytidine, decitabine, or low-dose cytarabine. For example:

  • Day 1: Venclexta 100mg once daily
  • Day 2: Venclexta 200mg once daily
  • Day 3: Venclexta 400mg once daily
  • Day 4 onwards: Venclexta 400mg once daily in combination with azacytidine or decitabine OR Venclexta 600mg once daily in combination with low-dose cytarabine.

    • Venclexta is continued on a once-daily dosing cycle at these dosages until disease progression or unacceptable toxicity is observed. Venclexta should be taken with food and at approximately the same time each day. Tablets should be swallowed whole and not crushed, chewed, or broken before swallowing.

    Venclexta (venetoclax) is approved to treat AML in adults aged 75 years or older, or in those with other medical conditions that prevent the use of intensive induction chemotherapy.

    Note that Venclexta has a different dosage schedule when used to treat CLL (chronic lymphocytic leukemia) and SLL (small lymphocytic lymphoma).

    How does Venclexta work?

    Venclexta works by inhibiting BCL-2, which is a group of proteins that are responsible for regulating cell death by either inhibiting or inducing apoptosis. Apoptosis is an ordered form of cell death in which the contents of the cell are “packaged” for collection by immune cells. It is different from the way cells die due to an injury.

    In certain cancers, such as CLL (chronic lymphocytic leukemia) and AML (acute myeloid leukemia) there is an abundance of BCL-2 on the surface of CLL and AML cells. This overexpression of BCL-2 allows tumor cells to survive for longer and has been associated with resistance to chemotherapy treatments. Laboratory research has shown that Venclexta binds to this protein and kills cancerous CLL and AML lymphocytes.

    Related medical questions

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords